Antibody-Drug Conjugates (ADCs) are a powerful class of therapeutics, combining the targeting precision of antibodies with the potency of small molecule drugs. Their success depends on reliable reagents and expert support throughout the development process.
At CUSABIO, we bring years of expertise in protein, antibody, and ELISA kit development to offer tailored products and services that support nearly every stage of ADC research, with a particular focus on early-stage, preclinical, and clinical studies.
Our ADC solutions include:
Whether you're in early-stage research, preclinical development, or clinical trials, our solutions are designed to help you move forward with confidence.
Click to known moremRNA vaccines represent a groundbreaking immunization technology harnessing the biological properties of messenger RNA (mRNA) to induce immune responses.
With years of expertise in protein, antibody, and ELISA kit development, CUSABIO possesses an extensive range of research reagents for viral studies and provides high-quality technical services. We are dedicated to supporting various stages of mRNA vaccine development, including early-stage research, production, quality control, and immune potency testing. Our commitment is to advance the progress of mRNA vaccine research.
Chimeric Antigen Receptor T (CAR-T) cell therapy is an individual cell-based technique that genetically treated T cells removed from patients in the lab and produce special receptors called chimeric antigen receptors, or CARs.
With years of expertise in protein, antibody, and ELISA kit development, CUSABIO possesses an extensive range of research reagents for viral studies and provides high-quality technical services. We are dedicated to supporting various stages of CAR-T cell therapy development, including CAR development, CAR-T preparation, CAR-T cell quality control and preclinical evaluation.